LTR 155: Leverage VIP to Move from Compliance to Capability

LTR 155: Leverage VIP to Move from Compliance to Capability

From Let's Talk Risk! with Dr. Naveen Agarwal by Casual and informal conversations about practical aspects of medical device risk management.

May 15, 2026 · 26 min

About this episode

The episode discusses how the Voluntary Improvement Program (VIP) can enhance quality maturity in MedTech beyond mere compliance.

Summary “Compliance alone does not drive quality” In this Let’s Talk Risk! conversation , host Naveen Agarwal speaks with Mike Cook about the the Voluntary Improvement Program (VIP), and how it can help MedTech leaders go beyond inspection readiness toward true quality maturity. Mike explains how VIP grew out of FDA’s Case for Quality initiative, why the program uses a maturity-appraisal model rather than a traditional audit model, and how organizations can use it to surface operational weaknesses, strengthen quality culture, and translate quality improvement into business language. The conversation also explores why many companies struggle to make the business case for proactive QMS improvement, how VIP may help organizations prepare for the expectations of QMSR, and why quality leaders need to connect risk reduction, operational excellence, and sustainable business performance. Listen to the full 30-minute podcast or jump to a section of interest listed below. Chapters 00:00 – Introduction 01:40 – From Case for Quality to VIP 03:45 – What makes VIP different from an audit 07:40 – How appraisals reveal QMS maturity 11:00 – Translating quality into business language 13:00 – Why…

People in this episode

Host: Naveen Agarwal

Guest: Mike Cook

Topics covered

  • quality management
  • regulatory compliance
  • operational excellence
  • risk reduction
  • business performance
  • quality culture

Keywords

  • Voluntary Improvement Program
  • quality maturity
  • FDA
  • MedTech
  • QMS
  • risk management
  • business case
  • operational weaknesses

Mentioned in this episode

Organizations: FDA, MedTech, QMSR, VIP, Case for Quality

More episodes of Let's Talk Risk! with Dr. Naveen Agarwal

Explore listener stats, chart rankings, contacts and more on the Let's Talk Risk! with Dr. Naveen Agarwal podcast page.